08:00 , Dec 4, 2000 |  BC Week In Review  |  Clinical News

ALG889: Began Phase I trial

Allergene Inc., San Mateo, Calif.   Product: ALG889   Business: Infectious diseases   Therapeutic category: Immune modulation   Target: T cells   Description: T cell receptor peptide immunomodulator   Indication: Treat HIV infection/AIDS   Status:...
07:00 , Jul 27, 1998 |  BC Week In Review  |  Company News

Allergene scientific advisory board update

Allergene Inc., San Mateo, Calif.   Business: Autoimmune/Inflammation   Appointed: Baruch Blumberg, professor of medicine and anthropology at the University of Pennsylvania  ...
07:00 , Jun 15, 1998 |  BC Week In Review  |  Clinical News

Allergene regulatory update

Allergene received U.S. Patents Nos. 5,512,283 and 5,643,572. The '283 patent claims antibodies to dust mites and their immunodominant epitopes. The '572 patent claims antibodies to urushiol, the oil in poison ivy and poison oak...
07:00 , May 26, 1998 |  BC Week In Review  |  Company News

Allergene, University of Arizona deal

Allergene acquired exclusive rights from the university to ALG889 , a T cell receptor peptide that the company said reverses some immune system abnormalities seen in HIV infection and other immune system disorders. Allergene Inc.,...
07:00 , Jun 21, 1993 |  BioCentury  |  Finance

Regulatory antibody strategy vs. allergies

Regulatory antibody strategy vs. allergies Allergene Inc. , which is developing regulatory antibodies to treat allergic diseases, told BioCentury that it is looking to raise a second venture round of about $5 million from either...